Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European Opportunities Loom For Value Added Medicines

But Sales Still Lag US, With EU Legislative Review Set To Address Sector’s Need For Reform

Executive Summary

Upcoming opportunities facilitated by the EU’s pharma legislation review were highlighted at Medicines for Europe’s fifth annual value added medicines conference, held in Brussels in early November. However, enthusiasm was tempered with acknowledgements that the European sector current lags behind the US and needs further reform to attract investment.

You may also be interested in...

Burt Succeeds Narayan As European Value Added Medicines Chair

At Medicines for Europe’s fifth annual value added medicines conference, the association announced that Pharmanovia CEO James Burt would take over as chair of its value added medicines sector group from Viatris executive Arun Narayan.

UK’s ‘Pioneering’ Medicines Repurposing Program Delivers First License

Now that the first license for a drug has been obtained in partnership with the program, work will begin to ensure other companies that make the product adopt the new licensed indication.

Fresenius And Formycon File Ustekinumab In US

Partners Fresenius Kabi and Formycon have submitted a US filing for their FYB202 ustekinumab biosimilar rival to Stelara.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts